SOUTH EASTON, Mass., March 31, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2013 financial results and to provide a business update.  Anyone interested may listen to the teleconference either by telephone (live) or through a replay on the Company's website.  The teleconference information is provided below:

Date:  Tuesday, April 1, 2014
Time:  4:15 PM Eastern Daylight Time (EDT)

To attend this teleconference via telephone:
Dial-in: (800) 875-3456 (U.S.); (800) 648-0973 (Canada); (302) 607-2001 (International)
Verbal Passcode (to be given to the operator): VS78313
Conference ID:  880058

The teleconference will include a Company presentation followed by a question & answer period.

For those unable to participate in the live teleconference, a replay will be available approximately four hours after the call and will be accessible through the Company's website for 30 days. 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following link: http://www.pressurebiosciences.com    
Please visit us on Facebook, LinkedIn, and Twitter. 

Investor Contacts:
Richard T. Schumacher, President & CEO
Richard P. Thomley, Acting CFO
Pressure BioSciences, Inc.
(T) 508-230-1828

SOURCE Pressure BioSciences, Inc.